DAX24.340 +0,2%Est505.746 -0,1%MSCI World4.343 -0,1%Top 10 Crypto10,94 -5,7%Nas23.593 -0,1%Bitcoin74.296 +0,2%Euro1,1776 ±0,0%Öl60,64 -2,6%Gold4.533 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Rheinmetall 703000 DroneShield A2DMAA Allianz 840400 Amazon 906866 Tesla A1CX3T Nike 866993 BYD A0M4W9 Bayer BAY001 Lufthansa 823212 Deutsche Telekom 555750 D-Wave Quantum A3DSV9 Alphabet A (ex Google) A14Y6F Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Hedera: So viel Verlust wäre bei einem Investment von vor 1 Jahr angefallen Hedera: So viel Verlust wäre bei einem Investment von vor 1 Jahr angefallen
So viel Verlust hätte eine Investition in Toncoin von vor 1 Jahr eingebracht So viel Verlust hätte eine Investition in Toncoin von vor 1 Jahr eingebracht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Spyre Therapeutics Aktie

Kaufen
Verkaufen
28,80 EUR +0,60 EUR +2,13 %
FSE
32,95 USD -0,09 USD -0,27 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,18 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3D4LY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00773J2024

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSYRE

Spyre Therapeutics Aktien News

DatumMeistgelesen
PR NewswireSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on ...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
ZacksWall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
PR NewswireSpyre Therapeutics to Participate in Upcoming June Investor Conferences
ZacksHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
PR NewswireSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics to Participate in Upcoming March Investor Conferences
PR NewswireSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
ZacksCan Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Added to the Nasdaq Biotechnology Index
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR NewswireSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disea...
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment ...
PR NewswireSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in Upcoming November Investor Conferences
PR NewswireSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combin...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
PR NewswireSpyre Therapeutics to Participate in Upcoming Investor Conference
PR NewswireSpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics News

Spyre Therapeutics News: auf dieser Seite finden Sie alle Spyre Therapeutics News und Nachrichten zur Spyre Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Spyre Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Spyre Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.